Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial
Ming Kai Lam, Hanim Sen, Kenneth Tandjung, K Gert van Houwelingen, Arie G de Vries, Peter W Danse, Carl E Schotborgh, Martijn Scholte, Marije M Löwik, Gerard C M Linssen, Maarten J Ijzerman, Job van der Palen, Carine J M Doggen, Clemens von Birgelen, Ming Kai Lam, Hanim Sen, Kenneth Tandjung, K Gert van Houwelingen, Arie G de Vries, Peter W Danse, Carl E Schotborgh, Martijn Scholte, Marije M Löwik, Gerard C M Linssen, Maarten J Ijzerman, Job van der Palen, Carine J M Doggen, Clemens von Birgelen
Abstract
Aim: To evaluate the safety and efficacy of 2 novel drug-eluting stents (DES) with biodegradable polymer-based coatings versus a durable coating DES.
Methods and results: BIO-RESORT is an investigator-initiated, prospective, patient-blinded, randomized multicenter trial in 3540 Dutch all-comers with various clinical syndromes, requiring percutaneous coronary interventions (PCI) with DES implantation. Randomization (stratified for diabetes mellitus) is being performed in a 1:1:1 ratio between ORSIRO sirolimus-eluting stent with circumferential biodegradable coating, SYNERGY everolimus-eluting stent with abluminal biodegradable coating, and RESOLUTE INTEGRITY zotarolimus-eluting stent with durable coating. The primary endpoint is the incidence of the composite endpoint target vessel failure at 1 year, consisting of cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization. Power calculation assumes a target vessel failure rate of 8.5% with a 3.5% non-inferiority margin, giving the study a power of 85% (α level .025 adjusted for multiple testing). The impact of diabetes mellitus on post-PCI outcome will be evaluated. The first patient was enrolled on December 21, 2012.
Conclusions: BIO-RESORT is a large, prospective, randomized, multicenter trial with three arms, comparing two DES with biodegradable coatings versus a reference DES with a durable coating in 3540 all-comers. The trial will provide novel insights into the clinical outcome of modern DES and will address the impact of known and so far undetected diabetes mellitus on post-PCI outcome.
Trial registration: ClinicalTrials.gov NCT01674803.
Copyright © 2014 The Authors. Published by Mosby, Inc. All rights reserved.
Source: PubMed